Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.59 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.59 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.59 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 13/20 | 0.52 |
| ▸ | ENTPD2 | Q9Y5L3 | 2/20 | 0.50 |
| ▸ | P2RY6 | Q15077 | 10/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.48 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4950387 | 0.87 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL10718479 | 0.87 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL437017 | 0.85 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL525149 | 0.85 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL22124733 | 0.84 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL6913156 | 0.84 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Ammonia Solution, Strong SCHEMBL28250466 | 0.83 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL2988773 | 0.82 | SLC28A1 (0.59) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4420751 | 0.82 | SLC28A1 (0.59) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL14384430 | 0.81 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021261855-A1 | ZINC TRANSPORTER ACTIVATOR COMPOSITION | 주식회사 메타센테라퓨틱스 | 2021-12-30 | — | — | WO | claimed |
| US-20100272791-A1 | COMPOSITION HAVING EFFECT ON TREATMENT AND PREVENTION OF DRY EYE SYNDROME | MD BIOALPHA CO., LTD. (KR) | 2010-10-28 | — | — | US | claimed |
| US-20080311186-A1 | Composition Having Effect on Treatment and Prevention of Dry Eye Syndrome | MD BIOALPHA CO., LTD. (KR) | 2008-12-18 | — | — | US | claimed |
| CN-101316600-A | Composition effective for treatment and prevention of dry eye syndrome | MD BIOALPHA CO LTD (KR) | 2008-12-03 | — | — | CN | claimed |
| EP-1954295-A1 | COMPOSITION HAVING EFFECT ON TREATMENT AND PREVENTION OF DRY EYE SYNDROME | Md Bioalpha Co., Ltd. (KR) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061200-A1 | COMPOSITION HAVING EFFECT ON TREATMENT AND PREVENTION OF DRY EYE SYNDROME | MD BIOALPHA CO., LTD. (KR) | 2007-05-31 | — | — | WO | claimed |
| WO-2024162590-A1 | COMPOSITION FOR PREVENTING OR TREATING PROSTATIC HYPERTROPHY, CONTAINING, AS ACTIVE INGREDIENTS, SALVIA MILTIORRHIZA BUNGE EXTRACT, METAL MINERAL DIAMINATE AND URIDINE | 주식회사 건강중심주의 | 2024-08-08 | — | — | WO | disclosed |
| EP-4210709-A1 | 2',3'-DIACETYLURIDINE SUBSTITUTED WITH ACETOACETYL AT THE 5' POSITION | Wellstat Therapeutics Corporation (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2021261855-A1 | ZINC TRANSPORTER ACTIVATOR COMPOSITION | 주식회사 메타센테라퓨틱스 | 2021-12-30 | — | — | WO | disclosed |
| WO-2019112383-A1 | METAL MINERAL DIAMINATE AND PREPARATION METHOD THEREFOR | 윤주석 | 2019-06-13 | — | — | WO | disclosed |
| CN-107614699-A | Method for detecting agglutination and composition for practicing the method | 加利福尼亚大学董事会 | 2018-01-19 | — | — | CN | disclosed |
| US-20140057973-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND PREVENTING DISEASES RELATED TO JOINT AND CONNECTIVE TISSUE | PARK, YOO SIN (KR) | 2014-02-27 | — | — | US | disclosed |
| EP-2484348-A2 | PHARMACEUTICAL COMPOSITION FOR TREATING AND PREVENTING DISEASES INVOLVING JOINTS AND CONNECTIVE TISSUE | Lee, Il Hoon (KR) | 2012-08-08 | — | — | EP | disclosed |
| EP-1295892-A1 | ANTISENSE MOLECULES AND METHOD OF CONTROLLING EXPRESSION OF GENE FUNCTION BY USING THE SAME | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-0226753-B1 | ALPHA-TOCOPHEROL (HALO) URIDINE PHOSPHORIC ACID DIESTER, SALTS THEREOF, AND METHODS FOR PRODUCING THE SAME | Senju Pharmaceutical Co., Ltd. (JP) | 1991-04-10 | — | — | EP | disclosed |
| US-4742163-A | ANTITUMOR, ANTIINFLAMMATORY | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1988-05-03 | — | — | US | disclosed |
| EP-0226753-A2 | Alpha-tocopherol (halo) uridine phosphoric acid diester, salts thereof, and methods for producing the same | Senju Pharmaceutical Co., Ltd. (JP) | 1987-07-01 | — | — | EP | disclosed |
| EP-0216844-A1 | NUCLEIC ACID SEQUENCES ATTACHED TO MATERIALS SENSITIVE TO MAGNETIC FIELDS, AND METHODS OF ASSAY AND APPARATUS USING SUCH ATTACHED SEQUENCES. | GENETICS INTERNATIONAL INC. (GB) | 1987-04-08 | — | — | EP | disclosed |
| WO-1986005815-A1 | NUCLEIC ACID SEQUENCES ATTACHED TO MATERIALS SENSITIVE TO MAGNETIC FIELDS, AND METHODS OF ASSAY AND APPARATUS USING SUCH ATTACHED SEQUENCES. | GENETICS INTERNATIONAL INC. (GB) | 1986-10-09 | — | — | WO | disclosed |
| EP-0111299-A1 | Fluorine-containing uridine derivative and preparation and use thereof | Daikin Kogyo Co., Ltd. (JP) | 1984-06-20 | — | — | EP | disclosed |